RD

Vivos IncOOTC RDGL Stock Report

Last reporting period 30 Jun, 2024

Updated 22 Nov, 2024

Last price

Market cap $B

0.069

Micro

Exchange

OOTC - OTC

RDGL Stock Analysis

RD

Uncovered

Vivos Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-10/100

Low score

Market cap $B

0.069

Dividend yield

Shares outstanding

362.54 B

Vivos, Inc. is a radiation oncology medical device company. The company is headquartered in Richland, Washington. The company went IPO on 2001-08-08. The firm is engaged in the development of its yttrium-90 (Y-90) based brachytherapy device, RadioGel, for the treatment of non-resectable tumors. RadioGel is a device for human therapy for non-resectable cancers in humans. The company is a hydrogel liquid containing tiny Yttrium-90 phosphate microparticles that may be administered directly into a tumor. The Company’s IsoPet division is focused on bringing RadioGel yttrium-90 precision radionuclide therapy to veterinary oncologists to treat dogs, cats and horses suffering from cancerous tumors. The IsoPet solutions division used university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The firm is also engaged in developing a micro-injection system for small tumor therapy for treating cancerous thyroid lymph nodes.

View Section: Eyestock Rating